Biogen investors cheered the end of the company’s investment in the Phase III studies due to an unfavorable risk-benefit ratio – a widely expected result for the last clinical BACE inhibitor program.

The Swiss major's oncology business performed well in the third quarter with Kisqali sales catching the eye despite the specific problems that the pandemic has brought for breast cancer patients.

CEO Vas Narasimhan sees Novartis very much as an innovative company so the long-awaited strategic review of Sandoz suggests that the generics/biosimilars business could be spun off or sold fairly soon.